Crinetics Pharmaceuticals CRNX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $10.73M+74.2% | $6.16M+4,208% | $143K-86.1% | $1.03M+186% | $361K— | ||
| $200K— | —— | —— | —— | $0— | ||
| $10.53M— | —— | —— | —— | $361K+39.0% | ||
| 98.1%— | —— | —— | —— | 100%— | ||
| $100.08M+17.7% | $85.05M-6.0% | $90.46M+12.7% | $80.3M+5.3% | $76.24M+14.5% | ||
| —— | $47.83M0.0% | $47.83M0.0% | $47.83M0.0% | $47.83M+91.8% | ||
| $50.83M— | —— | $52.27M+4.9% | $49.84M+40.3% | $35.53M+26.1% | ||
| $151.11M— | —— | —— | —— | $111.77M+31.5% | ||
| -$140.38M-5.0% | -$133.67M+6.3% | -$142.59M-10.4% | -$129.11M-15.9% | -$111.41M-17.6% | ||
| -1,307.8%+862pp | -2,169.6%+97,541pp | -99,710.5%-87,188pp | -12,523%+18,337pp | -30,860.1%— | ||
| $12.66M+13.5% | $11.16M-11.1% | $12.54M-6.8% | $13.46M-9.3% | $14.83M+3.2% | ||
| $12.53M+13.6% | $11.03M-11.7% | $12.5M-7.3% | $13.48M-7.9% | $14.63M+3.4% | ||
| —— | $45K0.0% | $45K0.0% | $45K0.0% | $45K— | ||
| -$127.85M-4.1% | -$122.82M+5.6% | -$130.09M-12.5% | -$115.64M-19.5% | -$96.77M-20.1% | ||
| -1,191%+802pp | -1,993.4%+88,979pp | -90,972.7%-79,757pp | -11,216%+15,591pp | -26,807.2%— | ||
| -$1.23+4.7% | -$1.29+6.5% | -$1.38-12.2% | -$1.23-18.3% | -$1.04-19.5% | ||
| -$1.23+4.7% | -$1.29+6.5% | -$1.38-12.2% | -$1.23-18.3% | -$1.04-19.5% | ||
| 104.1M+10.7% | 94.1M-0.2% | 94.2M+0.5% | 93.8M+0.7% | 93.1M+15.2% | ||
| 104.1M+10.7% | 94.1M-0.2% | 94.2M+0.5% | 93.8M+0.7% | 93.1M+15.2% | ||
| -$130.96M-6.4% | -$123.14M+4.9% | -$129.52M-11.6% | -$116.02M-21.2% | -$95.74M-17.2% | ||
| —— | -$116.33M0.0% | -$116.33M0.0% | -$116.33M0.0% | -$116.33M-56.2% | ||
| $28K+123% | -$123K-486% | -$21K+38.2% | -$34K-667% | $6K— | ||
| -$3.15M— | —— | $594K+271% | -$347K-134% | $1.03M+196% | ||
| -$131K-4.8% | -$125K-155% | -$49K— | $0+100% | -$203K+6.9% | ||
| $10.73M+74.2% | $6.16M+4,208% | $143K-86.1% | $1.03M+186% | $361K— | ||
| -$140.38M-5.0% | -$133.67M+6.3% | -$142.59M-10.4% | -$129.11M-15.9% | -$111.41M-17.6% | ||
| -$139.22M-4.9% | -$132.67M+6.3% | -$141.57M-10.5% | -$128.15M-16.0% | -$110.48M-17.6% | ||
| -$139.22M-4.9% | -$132.67M+6.3% | -$141.57M-10.5% | -$128.15M-16.0% | -$110.48M-17.6% | ||
| -1,297%+856pp | -2,153.4%+96,849pp | -99,002.8%-86,573pp | -12,430%+18,174pp | -30,603.9%— | ||
| -$140.38M-5.0% | -$133.67M+6.3% | -$142.59M-10.4% | -$129.11M-15.9% | -$111.41M-17.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Crinetics Pharmaceuticals's profit margins?
- Gross margin is 150.0% and operating margin is -3020.3%, with a -2747.2% net margin.
- Where does Crinetics Pharmaceuticals's income statement data come from?
- Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.